BRAF and melanoma: For example, Erkes et al. showed that the combination of a BRAFi/MEKi treatment (currently FDA-approved for BRAF-mutated melanoma patients) with stimulation of the pyroptotic pathway, represents a potential salvage therapy for more resistant patients.